BioSpace News Archive

New subscription service, KardiaCare, helps users manage heart conditions, understand symptoms, and reduce risk for heart disease

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain of SARS-CoV-2, the coronavirus that causes COVID-19.

Transgene and Hypertrust Patient Data Care announced as a world premiere the first productive blockchain solution for clinical trials of personalized healthcare, leveraging the Hypertrust X-Chain for Clinical Trials product.

Hadassah Medical Center and Assuta Medical Center, two of the leading healthcare providers in Israel, have decided to digitize their pathology departments with a solution from international medical imaging IT and cybersecurity company Sectra.

CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays.

The MEDICREA® Group, pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI proprietary software platform, services and technologies, publishes sales for the first half of 2020.

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the results of an interim analysis from the company’s post-market BRAVO study evaluating the clinical performance of OviTex for the treatment of ventral hernias.

ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics.

LGC announced the acquisition of The Native Antigen Company, one of the world’s leading suppliers of high quality infectious disease antigens and antibodies.

Four months ago, Canada was unprepared for the first wave of the COVID-19 pandemic hitting Canadian soil but managed to flatten the curve.